NeuroSense Secures Brazilian Patent for PrimeC Through 2042
NeuroSense has been granted Brazilian Patent No. BR 112024007727-6 for its PrimeC ciprofloxacin-celecoxib composition, extending protection through October 2042. This follows prior U.S. (12,097,185) and Australian (2022370513) approvals, bolstering the company’s global IP estate ahead of Phase 3 ALS trial initiation.
1. Patent Grant Details
NeuroSense received Brazilian Patent No. BR 112024007727-6 on April 6, 2026, covering its PrimeC fixed-dose composition of ciprofloxacin and celecoxib, securing exclusive rights through October 2042.
2. Global IP Expansion
This grant follows approval of U.S. Patent No. 12,097,185 and Australian Patent No. 2022370513, strengthening NeuroSense’s multi-territory protection for PrimeC’s novel extended-release formulation.
3. Impact on PrimeC Development
The expanded IP estate supports long-term commercialization strategy and de-risks preparations for the Phase 3 PARAGON trial in ALS, leveraging PrimeC’s multi-target disease-modifying approach.